---
title: "TherapeuticsMD, Inc. (TXMD.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TXMD.US.md"
symbol: "TXMD.US"
name: "TherapeuticsMD, Inc."
industry: "Pharmaceuticals"
datetime: "2026-06-13T21:00:41.285Z"
locales:
  - [en](https://longbridge.com/en/quote/TXMD.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TXMD.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TXMD.US.md)
---

# TherapeuticsMD, Inc. (TXMD.US)

## Company Overview

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.therapeuticsmd.com](https://www.therapeuticsmd.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:13.000Z

**Overall: B (0.36)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 32 / 196 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 82.13% |  |
| Net Profit YoY | 108.52% |  |
| P/B Ratio | 0.94 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 25463596.40 |  |
| Revenue | 3353000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.32% | D |
| Profit Margin | 5.34% | C |
| Gross Margin | 100.00% | A |
| Revenue YoY | 82.13% | A |
| Net Profit YoY | 108.52% | A |
| Total Assets YoY | -1.71% | D |
| Net Assets YoY | 0.87% | C |
| Cash Flow Margin | 1493.85% | A |
| OCF YoY | 82.13% | A |
| Turnover | 0.09 | E |
| Gearing Ratio | 28.23% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - TherapeuticsMD, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "82.13%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "108.52%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.94",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "25463596.40",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3353000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.32%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "5.34%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "82.13%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "108.52%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.71%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.87%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "1493.85%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "82.13%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.09",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "28.23%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 142.25 | 54/196 | 100.03 | 85.47 | 65.15 |
| PB | 0.94 | 40/196 | 0.92 | 0.71 | 0.48 |
| PS (TTM) | 7.59 | 107/196 | 8.86 | 7.23 | 5.61 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2023-08-17T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.20 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TXMD.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TXMD.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TXMD.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TXMD.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**